Drug Manufacturers - Specialty & Generic · market cap $1.7b. Down 24% from 52-week high of $97.00 — deep drawdown territory. Revenue growing +44% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $105.78 (implying +43% upside).
Moat
ROE 20% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 168% of net income — earnings translate cleanly into cash. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Drug Manufacturers - Specialty & Generic · market cap $59.8b. Trading near 52-week high of $19.10 — momentum setup, limited technical margin of safety. PEG 0.42 — paying under fair value for the growth rate. 3 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $21.96 (implying +17% upside).
Moat
$59.8b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -3.5%) — path to GAAP profitability is the core thesis risk. Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. ROE -2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ANIP and TAK diverge
On the headline score the gap is 58.6 points in favor of ANIP. The widest single difference is Growth, where ANIP leads by 77.9 points.
GrowthANIP 92.6 · TAK 14.7ANIP +77.9
ValueANIP 92.0 · TAK 23.9ANIP +68.1
QualityANIP 66.4 · TAK 46.3ANIP +20.1
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is ANIP or TAK the better stock?
ANIP scores higher: ANIP 82.7, TAK 24.1 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do ANIP and TAK differ most?
The widest gap is growth, where ANIP leads by 78 points on the 0–100 pillar scale. ANIP leads all three pillars, so the gap is broad rather than a single-measure difference.
How are ANIP and TAK scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.